FINWIRES · TerminalLIVE
FINWIRES

Research Alert: Arx: Record Q1 Production As Shell Announces Cad22 Billion Acquisition

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

ARC Resources (ARX) delivered record Q1 production of 418,522 boe/day, up 12% Y/Y, with funds from operations of CAD967M (CAD1.70/share, +17% per share) and free funds flow of CAD459M (CAD0.81/share, +19% per share Y/Y). Strong natural gas pricing of CAD4.51/Mcf and higher volumes led to the outperformance, while the company returned CAD256M to shareholders (56% of free funds flow) through dividends and share repurchases. On April 27, ARX announced a CAD22B acquisition by Shell at CAD32.80/share, representing a 27% premium and validating the company's operational excellence. Management maintained 2026 guidance of 405,000-420,000 boe/day production and CAD1.8B-CAD1.9B in capital spending, though Q2 will see planned turnaround impacts. The quarter demonstrates why Shell pursued this strategic acquisition, as ARX achieved double-digit production growth and strong gas pricing realization. We expect shares to trade near the CAD32.80 offer price barring any closing complexities.

Related Articles

Asia

ICBC Sells 50 Billion Yuan Bonds

Industrial and Commercial Bank of China (HKG:1398, SHA:601398) or ICBC completed the issue of 50 billion yuan of four-year bonds carrying an interest rate of 1.79%, according to a Wednesday Hong Kong bourse filing.The lender has a conditional redemption right at the end of the third year.The firm intends to use proceeds to improve its total loss-absorbing capacity.

$HKG:1398$SHA:601398
Asia

DFZQ's Profit Climbs 11% in Q1

Orient Securities (HKG:3958) or DFZQ recorded an 11% rise in attributable profit in the first quarter of 2026 to 1.59 billion yuan from 1.44 billion yuan after adjustment a year prior, according to a Wednesday Hong Kong bourse filing.The securities company's basic EPS rose to 0.19 yuan from 0.16 yuan in the corresponding period of the previous fiscal year.Operating income jumped 5.3% to 4.09 billion yuan from 3.88 billion yuan in the year-ago period.

$HKG:3958
Research

Research Alert: Ionis Reports Strong Q1 Led By Commercial Momentum; Raises Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Ionis delivered robust Q1 2026 results with total revenue surging to $246M (+87% Y/Y), fueled by strong commercial execution and approximately $95M in R&D milestone payments. Product sales reached $43M compared to just $6M in the prior year period, with TRYNGOLZA generating $27M (+350% Y/Y) and DAWNZERA contributing $16M (+125% sequential growth). The accelerating momentum across its independent launch portfolio demonstrates strong commercial execution, in our view. Management raised 2026 revenue guidance substantially to $875M-$900M (from $800M-$825M) and improved operating loss guidance to $425M-$475M (from $500M-$550M). The company also increased olezarsen peak sales guidance to over $3B from over $2B, reflecting growing confidence in the severe hypertriglyceridemia market opportunity. With multiple regulatory catalysts ahead, including potential approvals for olezarsen and zilganersen, we believe Ionis appears well-positioned for continued growth.

$IONS